These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 16389458)

  • 1. Nucleoside and nucleotide inhibitors of HIV-1 replication.
    Vivet-Boudou V; Didierjean J; Isel C; Marquet R
    Cell Mol Life Sci; 2006 Jan; 63(2):163-86. PubMed ID: 16389458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase.
    Menéndez-Arias L
    Virus Res; 2008 Jun; 134(1-2):124-46. PubMed ID: 18272247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
    Miller V; Larder BA
    Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
    Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
    J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors.
    Domaoal RA; Demeter LM
    Int J Biochem Cell Biol; 2004 Sep; 36(9):1735-51. PubMed ID: 15183341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-Catalytic Complexes with Emtricitabine or Stavudine and HIV-1 Reverse Transcriptase Reveal New Mechanistic Insights for Nucleotide Incorporation and Drug Resistance.
    Bertoletti N; Chan AH; Schinazi RF; Anderson KS
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33096918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs).
    Sluis-Cremer N; Arion D; Parniak MA
    Cell Mol Life Sci; 2000 Sep; 57(10):1408-22. PubMed ID: 11078020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance issues with new nucleoside/nucleotide backbone options.
    Wainberg MA; Turner D
    J Acquir Immune Defic Syndr; 2004 Sep; 37 Suppl 1():S36-43. PubMed ID: 15319668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure, Synthesis and Inhibition Mechanism of Nucleoside Analogues as HIV-1 Reverse Transcriptase Inhibitors (NRTIs).
    Yoshida Y; Honma M; Kimura Y; Abe H
    ChemMedChem; 2021 Mar; 16(5):743-766. PubMed ID: 33230979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An introduction to nucleoside and nucleotide analogues.
    Squires KE
    Antivir Ther; 2001; 6 Suppl 3():1-14. PubMed ID: 11678469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Alcaro S; Alteri C; Artese A; Ceccherini-Silberstein F; Costa G; Ortuso F; Parrotta L; Perno CF; Svicher V
    Drug Resist Updat; 2011 Jun; 14(3):141-9. PubMed ID: 21295512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 polymerase inhibition by nucleoside analogs: cellular- and kinetic parameters of efficacy, susceptibility and resistance selection.
    von Kleist M; Metzner P; Marquet R; Schütte C
    PLoS Comput Biol; 2012 Jan; 8(1):e1002359. PubMed ID: 22275860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nucleoside-analog resistance mutations in HIV-1 reverse transcriptase and their influence on polymerase fidelity and viral mutation rates.
    Rezende LF; Prasad VR
    Int J Biochem Cell Biol; 2004 Sep; 36(9):1716-34. PubMed ID: 15183340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug resistance mutations in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase differentially affect the phosphorolysis-dependent primer unblocking activity in the presence of stavudine and zidovudine and its inhibition by efavirenz.
    Crespan E; Locatelli GA; Cancio R; Hübscher U; Spadari S; Maga G
    Antimicrob Agents Chemother; 2005 Jan; 49(1):342-9. PubMed ID: 15616314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 reverse transcriptase and antiviral drug resistance. Part 1.
    Das K; Arnold E
    Curr Opin Virol; 2013 Apr; 3(2):111-8. PubMed ID: 23602471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
    Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human immunodeficiency virus type 1: resistance to nucleoside analogues and replicative capacity in primary human macrophages.
    Perez-Bercoff D; Wurtzer S; Compain S; Benech H; Clavel F
    J Virol; 2007 May; 81(9):4540-50. PubMed ID: 17287264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elucidating molecular interactions of
    Hung M; Tokarsky EJ; Lagpacan L; Zhang L; Suo Z; Lansdon EB
    Commun Biol; 2019; 2():469. PubMed ID: 31872074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Essential benefits of nucleoside analogue regimens in failing therapy.
    Geretti AM
    J HIV Ther; 2004 May; 9(2):28-33. PubMed ID: 15238873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteochemometric modeling of the susceptibility of mutated variants of the HIV-1 virus to reverse transcriptase inhibitors.
    Junaid M; Lapins M; Eklund M; Spjuth O; Wikberg JE
    PLoS One; 2010 Dec; 5(12):e14353. PubMed ID: 21179544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.